MEDIFAST INC
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
MEDIFAST INC (MED) filed an SEC Form 8-K — Results of Operations and Financial Condition. Medifast Announces Third Quarter 2026 Financial Results October 26, 2026 BALTIMORE – (BUSINESS WIRE) — Medifast (NYSE: MED), the metabolic health and wellness company known for its science-backed comprehensive metabolic health system, Trilivy™, today reported results for the thir
Medifast reported Q3 Non-GAAP EPS of -$0.19, beating estimates by $0.16. Revenue was $72.05M, down 19.4% Y/Y but exceeding expectations by $0.75M. The company had 10,200 independent active earning coaches. According to the company, revenue decreased from $89.4M in the prior year period.
Medifast (MED) will report Q3 2026 earnings on October 26. Analysts expect revenue of $71.3M and a loss of $0.35 per share, according to estimates.
Over the past 7 days, AlphAI's AI scored 19 news stories mentioning MED (MEDIFAST INC). Coverage has skewed bearish: 5 bullish, 1 neutral, and 13 bearish.
Recent MED coverage spans earnings, insider activity and financial news.
In the last 30 days, MED insiders filed 2 SEC Form 4 transactions — no purchases and 2 sales ($226K). The most active reporter was Chard Daniel R with 2 filings. 100% of those filings were made under pre-arranged Rule 10b5-1 plans.
The earnings miss and widening loss suggest pressure on the stock.
Earnings miss on profitability despite modest beat on revenue.
Negative earnings estimate may weigh on the stock at the post‑market release.
Strategic shift may improve margins and drive top‑line growth, but execution risk remains.
Insider buying may signal confidence, modest upside potential.
AlphAI scores every news story that mentions MED with an AI model for sentiment and relevance, and aggregates insider trades from MEDIFAST INC's SEC EDGAR Form 4 filings. Figures refresh continuously.
MEDIFAST INC (MED) filed an SEC Form 8-K — Results of Operations and Financial Condition. Medifast Announces Third Quarter 2026 Financial Results October 26, 2026 BALTIMORE – (BUSINESS WIRE) — Medifast (NYSE: MED), the metabolic health and wellness company known for its science-backed comprehensive metabolic health system, Trilivy™, today reported results for the thir
3 min readMedifast reported Q3 Non-GAAP EPS of -$0.19, beating estimates by $0.16. Revenue was $72.05M, down 19.4% Y/Y but exceeding expectations by $0.75M. The company had 10,200 independent active earning coaches. According to the company, revenue decreased from $89.4M in the prior year period.
1 min readMedifast (MED) will report Q3 2026 earnings on October 26. Analysts expect revenue of $71.3M and a loss of $0.35 per share, according to estimates.
1 min readMedifast (MED) announced its MED 3.0 strategy, shifting focus to metabolic health under the Trilivy brand. The company aims to return to profitability by Q4 2026 through cost savings and revenue growth initiatives. MED's shares have gained 17.5% in six months, trading at a forward P/S ratio of 0.50. Analysts expect a 26.8% decline in current-year earnings but 54.8% growth next year.
2 min readOn August 28, 2026, 183 insider stock purchases were reported. Notable transactions include Klarna Group's CEO buying 692,506 shares for $9.95M, Medifast's Kiai Parsa purchasing 41,975 shares for $514,747, and Regenxbio's Ciongoli buying 53,407 shares for $499,675. Hawkins' Lange and FTC Solar's Sadasivam also made significant purchases.
1 min readKiai Parsa purchased 43,150 indirectly-held shares of MEDIFAST INC (MED) at $12.26 ($0.53M total) across 2 trades on 2026-08-26.
1 min readKiai Parsa purchased 4,329 indirectly-held shares of MEDIFAST INC (MED) at $12.00 across 2 trades on 2026-08-24.
1 min readKiai Parsa purchased 72,487 indirectly-held shares of MEDIFAST INC (MED) at an average of $11.63 ($11.60–$11.66, $0.84M total) across 4 trades over 2026-08-19 to 2026-08-20.
1 min readMedifast (NYSE: MED) shares rose 37.5% after Q2 results beat expectations and the company issued a stronger full-year outlook. Medifast reported a $0.28 per-share loss versus a $0.65 expected loss, and revenue of $76.38 million. It guided full-year GAAP EPS of $1.00 at the midpoint, versus analyst estimates.
4 min readMedifast (NYSE:MED) reported Q2 CY2026 revenue of $76.38M, down 27.6% year over year but 5.1% above expectations. Next-quarter revenue guidance was $70M at the midpoint, about 3.4% above analyst estimates. GAAP EPS loss was $0.28, worse than consensus. Shares rose 12.8% to $10.99.
3 min read
